LINC01882: LINC01882 is a long non-coding RNA (lncRNA) that is primarily expressed in T cells and plays a role in the abnormal immune mechanism of rheumatoid arthritis (RA) [PMC7994855]. Knockdown of LINC01882 in Jurkat T cells resulted in the upregulation of factors related to IL-2 regulation, such as the transcription factor ZEB1 and the kinase MAP2K4 [PMC7994855]. LINC01882 was found to be significantly downregulated in anti-CD3/CD28 activated primitive CD4+ T cells [PMC7994855]. SNPs in the PTPN2 locus, which are associated with autoimmune diseases including inflammatory bowel disease (IBD), are related to changes in LINC01882 expression [PMC7295799]. However, further analysis is needed to understand the relationship between LINC01882 and IBD [PMC7295799]. LINC01882 may participate in IL-2 expression, which is important for differentiation, immune responses, and homeostasis of various lymphocytes including regulatory T cells (Tregs) [PMC7295799]. The activation of T cells in RA involves LINC01882 [PMC6909907]. Autoimmune disease-associated SNPs at the PTPN2 locus are linked to differential DNA methylation at specific CpG sites downstream of PTPN2 as well as expression changes of LINC01882 and RP11-973H7.1 primarily observed in T cells from RA patients [PMC6909907]. Silencing LINC01882 in Jurkat T cells resulted in upregulation of six genes and downregulation of six genes, including MAP2K4 and ZEB1 which are involved with cytokine signaling response and IL-2 expression inhibition respectively [PMC6909907]. In summary, LINC01882 is a lncRNA primarily expressed in T cells that plays a role in the abnormal immune mechanism of RA and may be involved in IL-2 regulation and T cell activation. Further research is needed to understand its role in IBD [PMC7994855][PMC7295799][PMC6909907].